What Is GHRH(1-29)? Same as Sermorelin — Real Peptides

What Is GHRH(1-29)? Same as Sermorelin — Real Peptides

A researcher ordering peptides sees two product listings: one labeled 'GHRH(1-29)', the other 'sermorelin acetate'. The molecular weight matches. The sequence appears identical. The confusion is immediate. Are these the same compound, or is one a derivative or analogue?

We've guided research labs through this exact nomenclature question for years. The answer matters for protocol design, literature citations, and regulatory documentation. The three things most peptide guides never clarify: why two names exist for one molecule, when the distinction actually matters in research contexts, and which nomenclature standard your institution's ethics committee expects you to use.

Is GHRH(1-29) the same thing as sermorelin?

Yes. GHRH(1-29) and sermorelin are identical peptides. Both refer to the biologically active 29-amino-acid fragment of human growth hormone releasing hormone, with the same sequence starting at tyrosine-1 and ending at leucine-29. The only difference is nomenclature: GHRH(1-29) describes the peptide's structural origin, while sermorelin is the International Nonproprietary Name assigned by the World Health Organization for the same molecule when used in research or therapeutic contexts.

The nomenclature split isn't arbitrary. It reflects how peptides move from basic research into applied science. GHRH(1-29) is structural notation: parentheses denote which amino acid positions from the full 44-amino-acid native hormone are retained. Sermorelin is the WHO-assigned drug name, typically appearing with the salt designation 'sermorelin acetate' when formulated for injection. In biological mechanism, receptor binding affinity, half-life, and stimulation potency at the anterior pituitary, the two terms describe the same peptide without deviation. This article covers exactly why the dual nomenclature exists, when each name appears in peer-reviewed literature, and what preparation differences matter when sourcing research-grade material.

Why GHRH(1-29) and Sermorelin Are the Same Peptide

Growth hormone releasing hormone exists in the human hypothalamus as a 44-amino-acid peptide. But only the first 29 residues are required for full biological activity at the GHRH receptor (GHRHR). Amino acids 30 through 44 contribute nothing to receptor binding or signal transduction; they're structurally vestigial in vivo. When researchers in the 1980s isolated and sequenced native GHRH, they immediately tested truncated fragments to identify the minimal active sequence. The 1–29 fragment retained 100% of the parent hormone's potency in stimulating growth hormone secretion from somatotrophs in the anterior pituitary. Making it the logical candidate for synthetic production.

The peptide designation 'GHRH(1-29)' is structural shorthand: it tells you this molecule contains amino acid residues 1 through 29 from the native hormone, with tyrosine at position 1 and leucine at position 29. The WHO assigned the International Nonproprietary Name 'sermorelin' to this exact sequence when pharmaceutical interest emerged. That name stuck in regulatory and clinical contexts, while GHRH(1-29) remained the preferred notation in basic endocrinology research. The confusion arises because peptide suppliers use both terms interchangeably. Some list 'sermorelin' to align with clinical literature, others use 'GHRH(1-29)' to match structural biology nomenclature. Our team synthesizes every batch to the same 1–29 sequence regardless of which name appears on the label.

When Nomenclature Differences Actually Matter

The distinction between calling a peptide 'GHRH(1-29)' versus 'sermorelin' has zero impact on the molecule's structure or biological activity. But it determines how your work gets cited and whether regulatory reviewers flag inconsistencies. In peer-reviewed endocrinology journals, authors typically use 'GHRH(1-29)' when discussing receptor pharmacology or comparing structural analogues; 'sermorelin' appears more often in clinical trial reports or pharmacokinetic studies where the peptide is being evaluated as a therapeutic agent. If you're submitting an IACUC protocol or an NIH grant application, match the nomenclature standard used in your references. Switching between both terms in the same document raises red flags about whether you're discussing one compound or two.

Salt designation adds another layer: 'sermorelin acetate' specifies that the peptide is formulated as an acetate salt, the most common form for lyophilized research peptides because acetate counterions stabilize the powder during storage. When reconstituted in bacteriostatic water, the acetate dissociates, leaving free sermorelin in solution. GHRH(1-29) listed without a salt designation is often assumed to be the acetate form unless otherwise stated. But verifying this with your supplier before use eliminates ambiguity. The peptide sequence itself is unchanged; the acetate simply affects solubility and storage stability, not the amino acid chain.

Biological Activity and Receptor Binding Comparison

| Peptide Name | Amino Acid Sequence Length | GHRHR Binding Affinity (Ki) | GH Secretion Potency (vs Native GHRH) | Half-Life in Circulation | Clinical/Research Status | Bottom Line ||—|—|—|—|—|—|| GHRH(1-29) / Sermorelin | 29 residues (Tyr¹ to Leu²⁹) | 1.2 nM | 100% (equipotent to full-length GHRH at GHRHR) | ~10–15 minutes | FDA-approved 1997–2008, now research-only | Identical peptide. Nomenclature difference only. Full biological activity retained. || GHRH(1-44) (native hormone) | 44 residues | ~1.0 nM | 100% (reference standard) | ~7–10 minutes | Endogenous form, rarely synthesized | Longer but no functional advantage. Residues 30–44 are biologically inert at GHRHR. || Modified GH Secretagogues (e.g., CJC-1295) | 29–30 residues + modifications | Variable (0.5–5 nM) | Variable (50–200% depending on analogue) | 6–8 days (with DAC modification) | Research-only, not FDA-approved | Structural analogues designed to extend half-life. Not the same peptide as sermorelin. |

This table underscores a key point: GHRH(1-29) and sermorelin are functionally interchangeable because they are the same molecule. The 29-amino-acid sequence retains 100% of the biological activity of the full 44-residue native hormone. Receptor binding studies show identical Ki values, and in vitro assays measuring growth hormone release from cultured pituitary cells demonstrate equipotent dose-response curves. The shorter half-life (10–15 minutes) is inherent to the unmodified peptide structure; chemically modified analogues like CJC-1295 extend circulation time through albumin binding but represent distinct molecular entities with different regulatory and research considerations.

Key Takeaways

GHRH(1-29) and sermorelin are identical peptides containing the first 29 amino acids of growth hormone releasing hormone. The nomenclature difference is purely formal, with GHRH(1-29) used in structural biology contexts and sermorelin in clinical or pharmacological literature.

The 29-amino-acid sequence retains 100% of the biological activity of the full 44-residue native hormone at the GHRH receptor, with amino acids 30–44 contributing nothing to receptor binding or signal transduction.

Sermorelin acetate specifies the acetate salt form, the most common lyophilized preparation for research peptides. The acetate counterion stabilizes storage but dissociates upon reconstitution, leaving the active peptide unchanged.

Both terms refer to an FDA-approved compound from 1997–2008, now available exclusively for research use through licensed peptide suppliers. Regulatory status is identical regardless of which name appears on the label.

Peer-reviewed citations and institutional protocols should use consistent nomenclature within a single document. Switching between GHRH(1-29) and sermorelin without clarification can raise reviewer questions about whether multiple compounds are being discussed.

What If: GHRH(1-29) Same as Sermorelin Scenarios

What If a Supplier Lists Both Names for the Same Product?

Order confidently. It's the same peptide. Verify the amino acid sequence (Tyr-Ala-Asp-Ala-Ile… through Leu at position 29) and molecular weight (3357.9 Da for the acetate salt) match your protocol requirements. Reputable suppliers list both names because different research communities use different nomenclature conventions, and cross-referencing both terms improves product discoverability. At Real Peptides, we synthesize GHRH(1-29) to USP standards with verified sequence confirmation via mass spectrometry. The name on the label reflects customer preference, not batch variability.

What If a Protocol Specifies 'Sermorelin' But Your Lab Stocks 'GHRH(1-29)'?

Use what you have. They're interchangeable. The critical check is ensuring the molecular weight, sequence, and salt form match. If your stocked material is GHRH(1-29) acetate and the protocol calls for sermorelin acetate, the peptides are identical. Document the equivalence in your lab notebook with a citation to structural confirmation data, and proceed without substitution concerns. This scenario is common in labs that source peptides from multiple suppliers over time. Standardizing internal nomenclature reduces confusion, but the peptides themselves don't vary.

What If Literature Cites 'GHRH(1-29)' But Clinical Guidelines Use 'Sermorelin'?

Cross-reference both terms in your citations to demonstrate they're the same compound. WHO INN databases and PubChem entries link sermorelin and GHRH(1-29) as synonyms for CAS Registry Number 86168-78-7. When writing grants, protocols, or manuscripts, use the term that matches your primary references but include the alternate name in parentheses on first use. 'sermorelin (GHRH(1-29))' or 'GHRH(1-29) (sermorelin)'. To eliminate ambiguity for reviewers unfamiliar with peptide nomenclature conventions. The biological mechanism and experimental outcomes are identical regardless of which term you prioritize.

The Straightforward Truth About GHRH(1-29) and Sermorelin Nomenclature

Here's the straightforward answer: the peptide research community created this confusion by using two names for one molecule, and it persists because neither term is 'wrong'. GHRH(1-29) is structurally precise. It tells you exactly which amino acids from the native hormone are present. Sermorelin is clinically convenient. It's the WHO-assigned drug name, easier to cite in regulatory contexts. Neither name indicates a difference in purity, potency, or sequence. The only meaningful variable is whether your peptide supplier provides verified sequence confirmation and proper storage guidance. Because a correctly named peptide stored incorrectly degrades just as fast as a poorly labeled one.

The biological mechanism is identical: both peptides bind to GHRH receptors on somatotroph cells in the anterior pituitary, activate Gs-protein-coupled signaling pathways, increase intracellular cAMP, and stimulate growth hormone secretion. The receptor doesn't distinguish between a vial labeled 'GHRH(1-29)' and one labeled 'sermorelin'. It recognizes the 29-amino-acid sequence and responds accordingly. If you're designing experiments involving growth hormone axis modulation, focus on dosage, reconstitution protocols, and injection timing rather than agonizing over which name to use. The peptide works the same either way.

Common Research Applications and Protocol Considerations

GHRH(1-29). Whether you call it that or sermorelin. Is used primarily in research models studying growth hormone secretion dynamics, age-related somatopause, and pituitary function testing. In rodent models, subcutaneous administration at doses ranging from 10–100 μg/kg stimulates pulsatile growth hormone release within 15–30 minutes, with peak serum GH levels occurring 20–40 minutes post-injection. The peptide's short half-life (10–15 minutes in circulation) makes it ideal for acute stimulation studies where you need a defined temporal window. Longer-acting analogues like CJC-1295 produce sustained elevation but lose the pulsatile pattern that characterizes endogenous GHRH signaling.

Reconstitution requires bacteriostatic water or sterile saline; the lyophilized powder is stable at −20°C for 24–36 months, but once reconstituted, the peptide must be stored at 2–8°C and used within 28 days. We've seen labs lose entire batches by reconstituting at room temperature or storing reconstituted vials at −20°C. Freezing causes ice crystal formation that shears peptide bonds, rendering the material inactive. Dose calculations should account for the acetate salt: sermorelin acetate is ~90% peptide by mass, with the remainder being the acetate counterion. If your protocol specifies 100 μg of active peptide, you'll need ~111 μg of sermorelin acetate powder. Our synthesis process at Real Peptides includes third-party verification of peptide content per vial, eliminating guesswork in dose preparation.

When sourcing peptides, the key isn't whether the supplier calls it GHRH(1-29) or sermorelin. It's whether they provide HPLC purity data, mass spectrometry sequence confirmation, and proper cold-chain shipping. A vial labeled 'sermorelin' that spent three days at ambient temperature during transit is worthless, regardless of how impressive the product description sounds. Real labs doing serious work need verified peptides shipped on dry ice with temperature logging. The nomenclature is secondary to the material's integrity when it reaches your bench.

The peptide's biological activity is concentration-dependent but self-limiting: GHRH receptor saturation occurs at physiological doses, meaning that doubling the dose doesn't double the growth hormone response beyond a certain threshold. This ceiling effect is why dose-response curves in pituitary cell cultures plateau at 10–100 nM sermorelin. Higher concentrations don't increase maximal GH secretion, they just prolong the duration of receptor occupancy. For protocol design, this means starting with conservative doses and titrating based on measured GH levels rather than assuming more peptide equals better results.

Frequently Asked Questions

GHRH(1-29) and sermorelin are the exact same molecule — a 29-amino-acid peptide fragment of growth hormone releasing hormone, with the sequence running from tyrosine at position 1 to leucine at position 29. The only difference is nomenclature: GHRH(1-29) is the structural designation used in basic research, while sermorelin is the International Nonproprietary Name assigned by the WHO for the same peptide when referenced in clinical or pharmacological contexts. Both terms describe identical amino acid sequences, molecular weights, and biological activity at the GHRH receptor.

Suppliers list both names to accommodate different research communities and nomenclature conventions — structural biologists search for ‘GHRH(1-29)’ while clinical researchers use ‘sermorelin’. The dual listing improves product discoverability and eliminates confusion for labs cross-referencing protocols written in different nomenclature styles. Reputable suppliers verify the peptide sequence via mass spectrometry regardless of which name appears on the product label, ensuring consistency across batches.

Yes — GHRH(1-29) and sermorelin acetate are interchangeable as long as the molecular weight, sequence, and salt form match. The ‘acetate’ designation indicates the peptide is formulated as an acetate salt for lyophilization stability; upon reconstitution, the acetate dissociates, leaving free sermorelin. Verify sequence identity (molecular weight 3357.9 Da for the acetate salt) and document the equivalence in your lab records, but no substitution concerns exist between the two nomenclatures.

There is no difference in biological activity — GHRH(1-29) retains 100% of the potency of the full-length 44-amino-acid native hormone at the GHRH receptor. Receptor binding studies show identical Ki values (~1.0–1.2 nM), and in vitro assays measuring growth hormone secretion from pituitary cells demonstrate equipotent dose-response curves. Amino acids 30 through 44 in the native hormone contribute nothing to receptor binding or signal transduction; they are structurally vestigial, which is why the 1–29 fragment became the standard for synthetic production.

Store reconstituted GHRH(1-29) or sermorelin at 2–8°C (refrigerated) and use within 28 days. The lyophilized powder is stable at −20°C for 24–36 months before reconstitution, but once mixed with bacteriostatic water, the peptide degrades faster at room temperature and denatures if frozen — ice crystal formation during freezing shears peptide bonds, rendering the material inactive. Never store reconstituted peptide solutions at −20°C; refrigeration at 2–8°C is the only correct post-reconstitution storage method.

The acetate counterion does not affect biological activity — it dissociates upon reconstitution, leaving free sermorelin in solution. However, it does affect dosing calculations: sermorelin acetate is approximately 90% peptide by mass, with the remainder being the acetate salt. If your protocol specifies 100 μg of active peptide, you need ~111 μg of sermorelin acetate powder to deliver that amount. Reputable suppliers provide peptide content verification per vial to eliminate dosing guesswork.

Typical subcutaneous doses in rodent models range from 10–100 μg/kg, with peak serum growth hormone levels occurring 20–40 minutes post-injection. The peptide’s short half-life (10–15 minutes in circulation) produces acute, pulsatile GH secretion rather than sustained elevation. Higher doses beyond 100 μg/kg do not proportionally increase maximal GH response due to receptor saturation — GHRH receptor binding plateaus at physiological concentrations, so protocol design should focus on timing and measurement windows rather than escalating doses.

Use the term that matches your primary references but include the alternate name in parentheses on first use — ‘sermorelin (GHRH(1-29))’ or ‘GHRH(1-29) (sermorelin)’ — to eliminate ambiguity for reviewers. Peer-reviewed endocrinology journals often use ‘GHRH(1-29)’ in receptor pharmacology studies, while clinical trial reports favor ‘sermorelin’. Consistency within a single document is critical; switching between both terms without clarification raises reviewer concerns about whether you’re discussing one compound or two.

Sermorelin received FDA approval in 1997 for diagnostic use in growth hormone deficiency testing, but the sole approved product (Geref) was discontinued in 2008. Since then, sermorelin has been available exclusively for research purposes through licensed peptide suppliers operating under research-use exemptions. It is not approved for human therapeutic use outside of clinical trials, and compounded versions are not FDA-approved drug products — they are prepared for research applications under state pharmacy board oversight.

Reputable suppliers provide HPLC purity data (≥98% purity for research-grade material), mass spectrometry sequence confirmation matching the expected 29-amino-acid sequence, and peptide content verification per vial. Cold-chain shipping with dry ice and temperature logging is essential — peptides exposed to ambient temperature for extended periods during transit degrade rapidly. At minimum, request a Certificate of Analysis showing molecular weight confirmation (3357.9 Da for sermorelin acetate) and purity percentage before use in any protocol.